| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(2 years from now) | |
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(2 years from now) | |
| US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(5 years from now) | |
| US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(2 years from now) | |
| US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(8 years from now) | |
Zelboraf is owned by Hoffmann La Roche.
Zelboraf contains Vemurafenib.
Zelboraf has a total of 6 drug patents out of which 0 drug patents have expired.
Zelboraf was authorised for market use on 17 August, 2011.
Zelboraf is available in tablet;oral dosage forms.
Zelboraf can be used as treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test.
Drug patent challenges can be filed against Zelboraf from 18 August, 2015.
The generics of Zelboraf are possible to be released after 06 June, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
Dosage: TABLET;ORAL
ZELBORAF family patents
